We are live on ! Find out more
CGTX icon

Cognition Therapeutics
CGTX

46 hedge funds and large institutions have $8.82M invested in Cognition Therapeutics in 2024 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 14 increasing their positions, 7 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 7

2% less funds holding

Funds holding: 47 → 46 (-1)

4.93% less ownership

Funds ownership: 18.18% → 13.26% (-4.9%)

17% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 6

32% less capital invested

Capital invested by funds: $12.9M → $8.82M (-$4.09M)

Holders
46
Holders Change
-1
Holders Change %
-2.13%
% of All Funds
0.66%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
14
Reduced
7
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$450K
2
BlackRock
BlackRock
New York
+$193K
3
Geode Capital Management
Geode Capital Management
Massachusetts
+$119K
4
Envestnet Asset Management
Envestnet Asset Management
Illinois
+$59.8K
5
Citadel Advisors
Citadel Advisors
Florida
+$53.7K

Top Sellers

Rank Fund Capital Flow
1
ACM
AIGH Capital Management
Maryland
-$3.18M
2
CCM
Corsair Capital Management
New York
-$414K
3
HWM
Hohimer Wealth Management
Washington
-$410K
4
TIM
Timelo Investment Management
Ontario, Canada
-$238K
5
CC
Carlson Capital
Texas
-$148K
Name Holding Trade Value Shares
Change 		Change in
Stake
Envestnet Asset Management
26
Envestnet Asset Management
Illinois
$49.8K +$59.8K +30,000 New
Citadel Advisors
27
Citadel Advisors
Florida
$44.7K +$53.7K +26,950 New
NFC
28
Northeast Financial Consultants
Connecticut
$40.7K – – –
HighTower Advisors
29
HighTower Advisors
Illinois
$38K – – –
Baird Financial Group
30
Baird Financial Group
Wisconsin
$37.2K – – –
GC
31
Gratus Capital
Georgia
$30.6K – – –
Millennium Management
32
Millennium Management
New York
$22.6K +$27.2K +13,624 New
SAF
33
Smith Anglin Financial
Texas
$19.9K – – –
Charles Schwab
34
Charles Schwab
California
$19.9K – – –
TRCT
35
Tower Research Capital (TRC)
New York
$17.6K +$8.4K +4,213 +66%
Susquehanna International Group
36
Susquehanna International Group
Pennsylvania
$16.9K +$20.3K +10,182 New
RJA
37
Raymond James & Associates
Florida
$16.6K – – –
Northwestern Mutual Wealth Management
38
Northwestern Mutual Wealth Management
Wisconsin
$9.74K – – –
Bank of America
39
Bank of America
North Carolina
$8.66K +$435 +218 +4%
Morgan Stanley
40
Morgan Stanley
New York
$4.98K – – –
BCA
41
Bray Capital Advisors
Florida
$3.73K – – –
SSB
42
Sandy Spring Bank
Maryland
$3.32K – – –
Wells Fargo
43
Wells Fargo
California
$1.66K +$1.7K +854 +585%
Royal Bank of Canada
44
Royal Bank of Canada
Ontario, Canada
$1K +$666 +334 +8,350%
OWA
45
Opal Wealth Advisors
New York
$830 +$997 +500 New
Fidelity Investments
46
Fidelity Investments
Massachusetts
$168 +$199 +100 +10,000%
HWM
47
Hohimer Wealth Management
Washington
– -$410K -225,000 Closed
LCS
48
Levin Capital Strategies
New York
– -$54.6K -30,000 Closed
Acadian Asset Management
49
Acadian Asset Management
Massachusetts
– -$23K -12,691 Closed
Qube Research & Technologies (QRT)
50
Qube Research & Technologies (QRT)
United Kingdom
– -$3.86K -2,121 Closed
1
2
3

CGTX Hedge Fund Activity: Q2 2024 in Review

46 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Cognition Therapeutics (CGTX) for Q2 2024, worth a combined $8.82M — down 32% from $12.9M a quarter earlier.

Sellers outnumbered buyers: 6 funds closed out of CGTX and 5 opened new positions — a net loss of 1 holder — while 7 trimmed existing stakes and 14 added.

The largest buyer was Vanguard Group, adding an estimated $450K. The largest seller was AIGH Capital Management, cutting an estimated $3.18M.

  • 46 institutional investors held Cognition Therapeutics (CGTX) as of Q2 2024, down from 47 in Q1 2024.
  • Funds reported $8.82M of Cognition Therapeutics stock for Q2 2024, down 32% quarter-over-quarter.
  • 5 funds opened new Cognition Therapeutics positions in Q2 2024 and 6 closed out, a net change of -1 holder.
  • The largest Cognition Therapeutics buyer in Q2 2024 was Vanguard Group, an estimated $450K added.
  • The largest Cognition Therapeutics seller in Q2 2024 was AIGH Capital Management, an estimated $3.18M sold.

Based on aggregated 13F filings for Q2 2024.